MedTrace Logo

APACC Study:Prospective Study on Aspirin Efficacy in Reducing Colorectal Adenoma Recurrence

NCT00224679 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2012-06-05

No results posted yet for this study

Summary

Experimental and epidemiologic studies have suggested that aspirin intake reduces the risk for colorectal cancer. In the APACC study we randomly assigned 291 patients to daily Aspirin or Placebo for 4 years. However, the available data are not sufficient to serve as the basis for firm recommendations

Conditions

  • Colon Adenomas

Interventions

DRUG

Aspirin

Sponsors & Collaborators

  • Société Nationale Française de Gastroentérologie

    collaborator OTHER

  • Ministry of Health, France

    collaborator OTHER_GOV

  • Sanofi-Synthelabo

    collaborator INDUSTRY

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Stanislas CHAUSSADE, MD · Assistance Publique - Hôpitaux de Paris

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-03-31
Completion
1999-03-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00224679 on ClinicalTrials.gov